Acute dopamine D1 and D2 receptor stimulation does not modulate mismatch negativity (MMN) in healthy human subjects

被引:52
作者
Leung, Sumie
Croft, Rodney J.
Baldeweg, Torsten
Nathan, Pradeep J.
机构
[1] Swinburne Univ Technol, Brain Sci Inst, Melbourne, Vic 3122, Australia
[2] Swinburne Univ Technol, Fac Life & Social Sci, Brain Sci Inst, Biol Psychiat Res Unit, Melbourne, Vic, Australia
[3] Monash Univ, Sch Psychol Psychiat & Psychol Med, Behav Neurosci Lab, Melbourne, Vic 3004, Australia
[4] UCL, Inst Child Hlth, London WC1N 1EH, England
[5] Great Ormond St Hosp Sick Children, London WC1N 3JH, England
基金
英国医学研究理事会;
关键词
mismatch negativity (MMN); dopamine (DA); D1; receptors; D2; schizophrenia; glutamate; NMDA receptors;
D O I
10.1007/s00213-007-0865-1
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale Schizophrenia is commonly associated with an impairment in pre-attentive change detection, as represented by reduced mismatch negativity (MMN), an auditory event related potential. While the neurochemical basis of MMN has been linked to the integrity of the glutamatergic system involving N-methyl-D-aspartate (NMDA) receptors, the role of the dopaminergic system and in particular, the role of D-1 and D-2 receptors on MMN is yet to be determined. Objectives The aim of the present project was to investigate the acute effects of dopamine D-2 (bromocriptine) and D-1/D-2 (pergolide) receptor stimulation on the human MMN in healthy subjects. Methods Fifteen healthy male subjects participated in a double-blind, placebo-controlled, cross-over design in which each subject was tested under three acute treatment conditions separated by a 1-week wash out period; placebo, bromocriptine (2.5 mg) and pergolide (0.1 mg). The subjects were exposed to a duration-MMN paradigm with 50 ms standard tones (91%) and 100 ms deviant tones (9%). Results The results showed that neither D-2 receptor stimulation with bromocriptine, nor simultaneous D-1 and D-2 receptor stimulation with pergolide, modulated MMN. Conclusions These findings suggest that acute D-1 and D-2 receptor stimulation does not modulate MMN. While the role of dopamine cannot be completely ruled out, the findings support the view that the aberrant MMN reported in schizophrenia may be linked primarily to glutamate dysfunction involving NMDA receptors.
引用
收藏
页码:443 / 451
页数:9
相关论文
共 63 条
[1]   Tryptophan depletion effects on EEG and MEG responses suggest serotonergic modulation of auditory involuntary attention in humans [J].
Ahveninen, J ;
Kähkönen, S ;
Pennanen, S ;
Liesivuori, J ;
Ilmoniemi, RJ ;
Jääskeläinen, IP .
NEUROIMAGE, 2002, 16 (04) :1052-1061
[2]   COMT Val108/158Met modifies mismatch negativity and cognitive function in 22q11 deletion syndrome [J].
Baker, K ;
Baldeweg, T ;
Sivagnanasundaram, S ;
Scambler, P ;
Skuse, D .
BIOLOGICAL PSYCHIATRY, 2005, 58 (01) :23-31
[3]   Nicotinic modulation of human auditory sensory memory: Evidence from mismatch negativity potentials [J].
Baldeweg, T ;
Wong, D ;
Stephan, KE .
INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY, 2006, 59 (01) :49-58
[4]   Mismatch negativity potentials and cognitive impairment in schizophrenia [J].
Baldeweg, T ;
Klugman, A ;
Gruzelier, J ;
Hirsch, SR .
SCHIZOPHRENIA RESEARCH, 2004, 69 (2-3) :203-217
[5]   Impairment in frontal but not temporal components of mismatch negativity in schizophrenia [J].
Baldeweg, T ;
Klugman, A ;
Gruzelier, JH ;
Hirsch, SR .
INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY, 2002, 43 (02) :111-122
[6]   The modulatory effects of dopamine D1 and D2 receptor function on object working memory in humans [J].
Bartholomeusz, CF ;
Box, G ;
Van Rooy, C ;
Nathan, PJ .
JOURNAL OF PSYCHOPHARMACOLOGY, 2003, 17 (01) :9-15
[7]   Mismatch negativity in schizophrenia: a family study [J].
Bramon, E ;
Croft, RJ ;
McDonald, C ;
Virdi, GK ;
Gruzelier, JG ;
Baldeweg, T ;
Sham, PC ;
Frangou, S ;
Murray, RM .
SCHIZOPHRENIA RESEARCH, 2004, 67 (01) :1-10
[8]  
Breier A, 1998, SYNAPSE, V29, P142, DOI 10.1002/(SICI)1098-2396(199806)29:2<142::AID-SYN5>3.0.CO
[9]  
2-7
[10]   Radioreceptor binding profile of the atypical antipsychotic olanzapine [J].
Bymaster, FP ;
Calligaro, DO ;
Falcone, JF ;
Marsh, RD ;
Moore, NA ;
Tye, NC ;
Seeman, P ;
Wong, DT .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :87-96